Evidence map›Paper›PMID 40341904›Full record

ArticleAdvanced healthcare materials2025

Development of DNase-1 Loaded Polymeric Nanoparticles Synthesized by Inverse Flash Nanoprecipitation for Neutrophil-Mediated Drug Delivery to In Vitro Thrombi.

Sophie Maiocchi, Erica E Burnham, Ana Cartaya, Veronica Lisi, Nancy Buechler, Rachel Pollard, Danial Babaki, Wolfgang Bergmeier, Nathalie M Pinkerton, Edward M Bahnson

Abstract read
In one paragraph

Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Engineering Nanoscale Drug Delivery Systems for Pain.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sophie MaiocchiDepartment of Cell Biology and Physiology, University of North Carolina, Chapel Hill, NC, 27599, USA.
Erica E BurnhamDepartment of Chemical and Biomolecular Engineering, Tandon School of Engineering, New York University, New York, NY, 11201, USA.
Ana CartayaDepartment of Cell Biology and Physiology, University of North Carolina, Chapel Hill, NC, 27599, USA.
Veronica LisiDepartment of Biomedical Engineering, Wake Forest University School of Medicine, Winston-Salem, NC, 27101, USA.
Nancy BuechlerDepartment of Biomedical Engineering, Wake Forest University School of Medicine, Winston-Salem, NC, 27101, USA.
Rachel PollardDepartment of Chemical and Biomolecular Engineering, Tandon School of Engineering, New York University, New York, NY, 11201, USA.
Danial BabakiDepartment of Cell Biology and Physiology, University of North Carolina, Chapel Hill, NC, 27599, USA.
Wolfgang BergmeierDepartment of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC, 27599, USA.
Nathalie M PinkertonDepartment of Chemical and Biomolecular Engineering, Tandon School of Engineering, New York University, New York, NY, 11201, USA.ORCID 0000-0001-9325-9764
Edward M BahnsonDepartment of Cell Biology and Physiology, University of North Carolina, Chapel Hill, NC, 27599, USA.ORCID 0000-0001-8578-0517

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5M
North Carolina Translational and Clinical Sciences Institute (NC TraCS)UM1TR004406 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI NICHOLAS J SHAHEEN · 2023 to 2026
$37.5M
UNC Neuroscience Center Research Cores: MicroscopyP30NS045892 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ZYLKA, MARK J. · 2003 to 2022
$11.5M
Preclinical CoreU54HD079124 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PIVEN, JOSEPH · 2013 to 2019
$8.0M
Targeted drug delivery for the treatment of cardiovascular disease and its clinical complicationsR00HL157690 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Sophie Maiocchi · 2024 to 2026
$747k
Zeiss LSM 980 Confocal MicroscopeS10OD032388 · OD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ITANO, MICHELLE S · 2022 to 2022
$597k
Targeted drug delivery for the treatment of cardiovascular disease and its clinical complicationsK99HL157690 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MAIOCCHI, SOPHIE · 2022 to 2023
$205k
Selective delivery of superoxide dismutase and catalase for restenosis preventionF31HL156427 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CARTAYA, ANA · 2021 to 2022
$74k
Burroughs Wellcome Fund CRTG1021186NCATS NIH HHS UM1 TR004406NCI NIH HHS P30 CA016086NCTraCS pilot grant supported by the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health UM1TR004406NHLBI NIH HHS F31 HL156427NHLBI NIH HHS K99 HL157690NHLBI NIH HHS R00 HL157690NICHD NIH HHS U54 HD079124NIH HHS S10 OD032388NIH-NHLBI to S.M. (K99&R00) and A.C. (F31) F31HL156427NIH-NHLBI to S.M. (K99&R00) and A.C. (F31) K99HL157690-01NIH-NHLBI to S.M. (K99&R00) and A.C. (F31) R00HL157690-03NINDS NIH HHS P30 NS045892ODCDC CDC HHS S10 OD032388
6 · The paper itself

Abstract

Activated neutrophils release Neutrophil Extracellular Traps (NETs), comprising decondensed chromatin, peroxidases, and serine proteases, which aid in host defense but are also implicated in thrombosis and resistance to thrombolysis. Recombinant DNase 1, which degrades NETs, may aid in thrombus dissolution synergistically with fibrinolytics. However, its short half-life and susceptibility to plasma proteases limit its therapeutic applicability. To address these limitations, DNase1 is encapsulated into polymeric nanoparticles (DNPs) using inverse Flash Nanoprecipitation (iFNP), a scalable nanoparticle synthesis technique. Previously only used with model proteins, the study demonstrates for the first time the feasibility of extending iFNP to the encapsulation of therapeutic proteins. Conditions that promote DNase1 solubility, preserve activity, and demonstrate release resulting in ex vivo NET degradation are detailed. Furthermore, the use of neutrophils, the source of NETs, as carriers for DNPs to enhance targeted delivery is investigated. These findings confirm that DNP-loaded neutrophils maintain key functionalities, including viability and oxidative burst, and associate with in vitro blood clots to deliver nanoparticles, and DNase1 protein. This study not only extends the feasibility of applying iFNP to encapsulate therapeutic proteins into polymeric nanoparticles, a promising alternative to lipid nanoparticles, but also contributes to the emerging literature on neutrophils as delivery vectors for nanocarriers.

Indexed as

Deoxyribonuclease IDrug Delivery SystemsNanoparticlesNeutrophilsPolymersThrombosisExtracellular TrapsHumansDeoxyribonuclease IPolymerscell mediated drug deliveryDNase 1inverse flash nanoprecipitationneutrophil extracellular trapsneutrophil nanomaterial interactionprotein delivery

Identifiers

PMID40341904
PMCPMC12148695

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.